280 related articles for article (PubMed ID: 11124893)
21. Protective role of melatonin in domoic acid-induced neuronal damage in the hippocampus of adult rats.
Ananth C; Gopalakrishnakone P; Kaur C
Hippocampus; 2003; 13(3):375-87. PubMed ID: 12722978
[TBL] [Abstract][Full Text] [Related]
22. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
[TBL] [Abstract][Full Text] [Related]
23. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra.
van Muiswinkel FL; de Vos RA; Bol JG; Andringa G; Jansen Steur EN; Ross D; Siegel D; Drukarch B
Neurobiol Aging; 2004 Oct; 25(9):1253-62. PubMed ID: 15312971
[TBL] [Abstract][Full Text] [Related]
24. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
25. Microglia in neurodegeneration: molecular aspects.
Gebicke-Haerter PJ
Microsc Res Tech; 2001 Jul; 54(1):47-58. PubMed ID: 11526957
[TBL] [Abstract][Full Text] [Related]
26. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
27. Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra.
Knott C; Stern G; Kingsbury A; Welcher AA; Wilkin GP
Parkinsonism Relat Disord; 2002 Jun; 8(5):329-41. PubMed ID: 15177062
[TBL] [Abstract][Full Text] [Related]
28. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
30. Anti-melanin antibodies are increased in sera in Parkinson's disease.
Double KL; Rowe DB; Carew-Jones FM; Hayes M; Chan DK; Blackie J; Corbett A; Joffe R; Fung VS; Morris J; Riederer P; Gerlach M; Halliday GM
Exp Neurol; 2009 Jun; 217(2):297-301. PubMed ID: 19289120
[TBL] [Abstract][Full Text] [Related]
31. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
[TBL] [Abstract][Full Text] [Related]
32. Role of p38 and inducible nitric oxide synthase in the in vivo dopaminergic cells' degeneration induced by inflammatory processes after lipopolysaccharide injection.
Ruano D; Revilla E; Gavilán MP; Vizuete ML; Pintado C; Vitorica J; Castaño A
Neuroscience; 2006 Jul; 140(4):1157-68. PubMed ID: 16713109
[TBL] [Abstract][Full Text] [Related]
33. COX-2 and neurodegeneration in Parkinson's disease.
Teismann P; Vila M; Choi DK; Tieu K; Wu DC; Jackson-Lewis V; Przedborski S
Ann N Y Acad Sci; 2003 Jun; 991():272-7. PubMed ID: 12846993
[TBL] [Abstract][Full Text] [Related]
34. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
35. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.
Mirza B; Hadberg H; Thomsen P; Moos T
Neuroscience; 2000; 95(2):425-32. PubMed ID: 10658622
[TBL] [Abstract][Full Text] [Related]
36. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease.
Schipper HM; Liberman A; Stopa EG
Exp Neurol; 1998 Mar; 150(1):60-8. PubMed ID: 9514830
[TBL] [Abstract][Full Text] [Related]
37. Non-autonomous cell death in Parkinson's disease.
Dawson TM
Lancet Neurol; 2008 Jun; 7(6):474-5. PubMed ID: 18485311
[No Abstract] [Full Text] [Related]
38. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease.
Scali C; Prosperi C; Vannucchi MG; Pepeu G; Casamenti F
Eur J Neurosci; 2000 Jun; 12(6):1900-12. PubMed ID: 10886331
[TBL] [Abstract][Full Text] [Related]
39. Nitric oxide in the pathogenesis of Parkinson's disease.
Gerlach M; Blum-Degen D; Lan J; Riederer P
Adv Neurol; 1999; 80():239-45. PubMed ID: 10410728
[No Abstract] [Full Text] [Related]
40. A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans.
Tomimoto H; Shibata M; Ihara M; Akiguchi I; Ohtani R; Budka H
Acta Neuropathol; 2002 Dec; 104(6):601-7. PubMed ID: 12410381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
